Mustang Bio, Inc. (MBIO) NASDAQ
0.70
-0.031(-4.26%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.70
-0.031(-4.26%)
Currency In USD
| Previous Close | 0.73 |
| Open | 0.71 |
| Day High | 0.72 |
| Day Low | 0.68 |
| 52-Week High | 7 |
| 52-Week Low | 0.53 |
| Volume | 39,604 |
| Average Volume | 40,941 |
| Market Cap | 5.27M |
| PE | -1.78 |
| EPS | -0.39 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 1.2 |
| Change | -0.03 |
CSE Bulletin: Consolidation - MindBio Therapeutics Corp. (MBIO)
Newsfile
Nov 04, 2025 10:11 PM GMT
Toronto, Ontario--(Newsfile Corp. - Le 4 novembre/November 2025) - MindBio Therapeutics Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every four hundre
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
GlobeNewswire Inc.
Jul 07, 2025 12:30 PM GMT
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
GlobeNewswire Inc.
Mar 05, 2025 9:15 PM GMT
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained comp